Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy

G. Bachmann, J. Bobula, S. Mirkin

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Objective To evaluate the effects of the tissue selective estrogen complex (TSEC) pairing bazedoxifene (BZA) with conjugated estrogens (CE) on sexual function and quality of life in postmenopausal women. Method s In this 12-week, double-blind, placebo-controlled study, postmenopausal, non-hysterectomized women (n=652) with symptoms of moderate to severe vulvar/vaginal atrophy were randomized to once-daily treatment with BZA 20mg/CE 0.45 or 0.625mg, BZA 20mg, or placebo. The Arizona Sexual Experiences (ASEX) Scale, Menopause-Specific Quality of Life (MENQOL) questionnaire, and Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) were secondary measures used to assess the effects of BZA/CE on sexual function, menopausal symptoms, and satisfaction with treatment, respectively. Results At week 12, both BZA/CE doses were associated with significant improvement in ease of lubrication score from baseline compared with placebo (p<0.05) on the ASEX scale, although there was no difference in the change in total score. The MENQOL questionnaire results at week 12 showed significant improvements in vasomotor function, sexual function and total scores with both BZA/CE doses vs. placebo or BZA 20mg (p<0.001). The MS-TSQ results showed that BZA/CE-treated subjects reported significantly greater overall satisfaction with treatment, as well as satisfaction with control of hot flushes during the day and night, effect on quality of sleep, and effect on mood or emotions, compared with subjects treated with placebo or BZA 20mg (all p<0.05). Conclusion Treatment with BZA/CE for 12 weeks was shown to significantly improve sexual function and quality-of-life measures in symptomatic postmenopausal women.

Original languageEnglish (US)
Pages (from-to)132-140
Number of pages9
JournalClimacteric
Volume13
Issue number2
DOIs
StatePublished - Apr 1 2010
Externally publishedYes

Fingerprint

Conjugated (USP) Estrogens
Atrophy
Quality of Life
Menopause
Placebos
Therapeutics
Lubrication
bazedoxifene
Sleep
Emotions
Estrogens
Surveys and Questionnaires

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Keywords

  • Bazedoxifene
  • Conjugated estrogens
  • Postmenopausal
  • Tissue selective estrogen complex
  • Tsec

Cite this

@article{9d40facc38e142b08c3700570d21b02f,
title = "Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy",
abstract = "Objective To evaluate the effects of the tissue selective estrogen complex (TSEC) pairing bazedoxifene (BZA) with conjugated estrogens (CE) on sexual function and quality of life in postmenopausal women. Method s In this 12-week, double-blind, placebo-controlled study, postmenopausal, non-hysterectomized women (n=652) with symptoms of moderate to severe vulvar/vaginal atrophy were randomized to once-daily treatment with BZA 20mg/CE 0.45 or 0.625mg, BZA 20mg, or placebo. The Arizona Sexual Experiences (ASEX) Scale, Menopause-Specific Quality of Life (MENQOL) questionnaire, and Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) were secondary measures used to assess the effects of BZA/CE on sexual function, menopausal symptoms, and satisfaction with treatment, respectively. Results At week 12, both BZA/CE doses were associated with significant improvement in ease of lubrication score from baseline compared with placebo (p<0.05) on the ASEX scale, although there was no difference in the change in total score. The MENQOL questionnaire results at week 12 showed significant improvements in vasomotor function, sexual function and total scores with both BZA/CE doses vs. placebo or BZA 20mg (p<0.001). The MS-TSQ results showed that BZA/CE-treated subjects reported significantly greater overall satisfaction with treatment, as well as satisfaction with control of hot flushes during the day and night, effect on quality of sleep, and effect on mood or emotions, compared with subjects treated with placebo or BZA 20mg (all p<0.05). Conclusion Treatment with BZA/CE for 12 weeks was shown to significantly improve sexual function and quality-of-life measures in symptomatic postmenopausal women.",
keywords = "Bazedoxifene, Conjugated estrogens, Postmenopausal, Tissue selective estrogen complex, Tsec",
author = "G. Bachmann and J. Bobula and S. Mirkin",
year = "2010",
month = "4",
day = "1",
doi = "10.3109/13697130903305627",
language = "English (US)",
volume = "13",
pages = "132--140",
journal = "Climacteric",
issn = "1369-7137",
publisher = "Informa Healthcare",
number = "2",

}

Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. / Bachmann, G.; Bobula, J.; Mirkin, S.

In: Climacteric, Vol. 13, No. 2, 01.04.2010, p. 132-140.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy

AU - Bachmann, G.

AU - Bobula, J.

AU - Mirkin, S.

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Objective To evaluate the effects of the tissue selective estrogen complex (TSEC) pairing bazedoxifene (BZA) with conjugated estrogens (CE) on sexual function and quality of life in postmenopausal women. Method s In this 12-week, double-blind, placebo-controlled study, postmenopausal, non-hysterectomized women (n=652) with symptoms of moderate to severe vulvar/vaginal atrophy were randomized to once-daily treatment with BZA 20mg/CE 0.45 or 0.625mg, BZA 20mg, or placebo. The Arizona Sexual Experiences (ASEX) Scale, Menopause-Specific Quality of Life (MENQOL) questionnaire, and Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) were secondary measures used to assess the effects of BZA/CE on sexual function, menopausal symptoms, and satisfaction with treatment, respectively. Results At week 12, both BZA/CE doses were associated with significant improvement in ease of lubrication score from baseline compared with placebo (p<0.05) on the ASEX scale, although there was no difference in the change in total score. The MENQOL questionnaire results at week 12 showed significant improvements in vasomotor function, sexual function and total scores with both BZA/CE doses vs. placebo or BZA 20mg (p<0.001). The MS-TSQ results showed that BZA/CE-treated subjects reported significantly greater overall satisfaction with treatment, as well as satisfaction with control of hot flushes during the day and night, effect on quality of sleep, and effect on mood or emotions, compared with subjects treated with placebo or BZA 20mg (all p<0.05). Conclusion Treatment with BZA/CE for 12 weeks was shown to significantly improve sexual function and quality-of-life measures in symptomatic postmenopausal women.

AB - Objective To evaluate the effects of the tissue selective estrogen complex (TSEC) pairing bazedoxifene (BZA) with conjugated estrogens (CE) on sexual function and quality of life in postmenopausal women. Method s In this 12-week, double-blind, placebo-controlled study, postmenopausal, non-hysterectomized women (n=652) with symptoms of moderate to severe vulvar/vaginal atrophy were randomized to once-daily treatment with BZA 20mg/CE 0.45 or 0.625mg, BZA 20mg, or placebo. The Arizona Sexual Experiences (ASEX) Scale, Menopause-Specific Quality of Life (MENQOL) questionnaire, and Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) were secondary measures used to assess the effects of BZA/CE on sexual function, menopausal symptoms, and satisfaction with treatment, respectively. Results At week 12, both BZA/CE doses were associated with significant improvement in ease of lubrication score from baseline compared with placebo (p<0.05) on the ASEX scale, although there was no difference in the change in total score. The MENQOL questionnaire results at week 12 showed significant improvements in vasomotor function, sexual function and total scores with both BZA/CE doses vs. placebo or BZA 20mg (p<0.001). The MS-TSQ results showed that BZA/CE-treated subjects reported significantly greater overall satisfaction with treatment, as well as satisfaction with control of hot flushes during the day and night, effect on quality of sleep, and effect on mood or emotions, compared with subjects treated with placebo or BZA 20mg (all p<0.05). Conclusion Treatment with BZA/CE for 12 weeks was shown to significantly improve sexual function and quality-of-life measures in symptomatic postmenopausal women.

KW - Bazedoxifene

KW - Conjugated estrogens

KW - Postmenopausal

KW - Tissue selective estrogen complex

KW - Tsec

UR - http://www.scopus.com/inward/record.url?scp=77249172217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249172217&partnerID=8YFLogxK

U2 - 10.3109/13697130903305627

DO - 10.3109/13697130903305627

M3 - Article

C2 - 19863455

AN - SCOPUS:77249172217

VL - 13

SP - 132

EP - 140

JO - Climacteric

JF - Climacteric

SN - 1369-7137

IS - 2

ER -